PRESS RELEASE published on 03/11/2024 at 08:00, 2 years 2 months ago Guerbet renforce son comité exécutif avec deux nouvelles nominations pour consolider son ambition à moyen et long terme. Guerbet renforce son comité exécutif avec deux nouvelles nominations pour consolider son ambition à moyen et long terme. Christine Allard et Eva Ohlsson rejoignent le comité exécutif de Guerbet en tant que Directrice des Affaires Publiques et Communication, et Directrice Ressources Humaines Innovation Comité Exécutif Nominations Guerbet Ambition
PRESS RELEASE published on 02/08/2024 at 17:45, 2 years 3 months ago Guerbet: Chiffre d’affaires 2023 Guerbet publie son chiffre d’affaires annuel: 785,7 M€, en hausse de 6,4% à TCC. Objectifs 2024: croissance attendue supérieure à 8% à périmètre constant et TCC. Taux de marge d’EBITDA retraité supérieur à 11% Croissance Chiffre D’affaires Guerbet Imagerie Médicale EBITDA Retraité
PRESS RELEASE published on 02/08/2024 at 17:45, 2 years 3 months ago Guerbet: 2023 revenue Guerbet reports 2023 revenue growth of 6.4% at constant exchange rates, with an anticipated 2024 revenue growth of over 8%. Restated EBITDA margin exceeds initial 11% target, while 2024 profitability target remains at 14.4% 2024 Guidance Guerbet Medical Imaging 2023 Revenue Restated EBITDA Margin
PRESS RELEASE published on 01/30/2024 at 17:45, 2 years 3 months ago Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years. Guerbet announces the passing of Michel Guerbet, son of the founder, and company director for over 30 years. The Group pays tribute to his exceptional leadership and significant contributions to the company's development Guerbet Michel Guerbet Company Director Medical Imaging Pharmaceutical Products
PRESS RELEASE published on 01/30/2024 at 17:45, 2 years 3 months ago Guerbet: Décès de Michel Guerbet, fils du fondateur et dirigeant de l’entreprise durant plus de 30 ans. Décès de Michel Guerbet, fils du fondateur et dirigeant de l’entreprise Guerbet pendant plus de 30 ans. L'entreprise rend hommage à sa contribution exceptionnelle à son développement. Guerbet, imagerie médicale, innovateur, R&D, actionnariat familial R&D Guerbet Imagerie Médicale Innovateur Actionnariat Familial
PRESS RELEASE published on 01/11/2023 at 18:23, 3 years 4 months ago Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
PRESS RELEASE published on 01/11/2023 at 18:23, 3 years 4 months ago Guerbet: Intrasense ouvre son capital au groupe Guerbet, qui annonce son intention de déposer un projet d’offre publique d’achat volontaire dans les mêmes conditions de prix
PRESS RELEASE published on 01/11/2023 at 10:57, 3 years 4 months ago Guerbet: Bilan semestriel du contrat de liquidité
Published on 05/23/2026 at 19:45, 9 hours 21 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 1 hour ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 2 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 2 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 2 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 16:30, 12 hours 35 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 13 hours 9 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 9 hours ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 19:35, 1 day 9 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026